CaseVu
Precipio Announces First IV-Cell™ Commercial Order From Northwell Health
Largest healthcare provider in New York becomes the first IV-Cell customer NEW HAVEN, CT, (December [...]
Dec
Precipio Announces The Resignation Of Samuel Riccitelli And The Introduction Of Richard Sandberg To Its Board Of Directors
Douglas Fisher, MD will assume the role of interim Chairman of the Board NEW HAVEN, [...]
Dec
Precipio Wins $750,000 Pharma Project
Testing and revenues will begin in Q4 and continue into Q1-2020 NEW HAVEN, CT, (November [...]
Precipio Reports Superior Performance For IV-Cell™ In Side-By-Side Analysis Conducted By Two Major External Laboratories
Testing yielded substantially better operational and clinical results, including the identification of a Leukemia missed when using [...]
Nov
Precipio Announces Q3-2019 Corporate Update Call For Shareholders
Conference Call to be held on Wednesday, November 13th, 2019 at 5:30 PM EST NEW [...]
Nov
Partners HealthCare And Precipio Enter Into Pathology Services Agreement
Continued Expansion of Academic Expertise Platform NEW HAVEN, CT, (October 9th, 2019) – Specialty diagnostics company Precipio, [...]
Oct
Precipio Announces Shareholder Update Call On Commercial Progress
Conference call to be held Thursday October 10th at 5:00PM EST NEW HAVEN, CT, (October [...]
Oct
Clinical Validations For IV-Cell™ And HemeScreen™ Completed
Orders expected from several major labs both domestically and internationally NEW HAVEN, CT, (September 26th, [...]
Sep
Precipio And University Of Pennsylvania Enter Into Joint Collaboration Agreement For Pathology Diagnostics
First cases already diagnosed and reported by Penn expert pathologists NEW HAVEN, CT, (September 5th, [...]
Sep
Precipio Pathology Sales Metrics Demonstrate Continuous Improvement In Q2 2019
Three key metrics indicate growth over prior Quarter and same Quarter of 2018 NEW HAVEN, [...]
Aug